Data / Research funding / Maryland / Dynport Vaccine Company, LLC
Dynport Vaccine Company, LLC: 6 NIH awards ($13.9M), fiscal years 2021 to 2026
Dynport Vaccine Company, LLC in Frederick, MD is funded under 6 NIH awards ($13.9M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- LXNEGTYDR755
- State
- Maryland
Awards
6 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Task B1: Phase I Clinical Trial to Evaluate a Therapeutic for Antibiotic Resistant Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,576,633 | May 13, 2021 | January 31, 2025 | BURMAN, BRIDGETT | reporter.nih.gov |
| Task A: Early Phase Clinical Trial Units (EPCTU) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,074,940 | January 14, 2022 | January 13, 2026 | SAVIOLAKIS, GEORGE | reporter.nih.gov |
| EVALUATION OF A MONOCLONAL ANTIBODY | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,213,178 | July 20, 2022 | July 18, 2023 | HART, MARY KATE | reporter.nih.gov |
| Task C: NIAID Preclinical Services for AMR Diagnostics Development | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $10,500 | June 20, 2023 | June 19, 2030 | KALLARKAL, ABRAHAM | reporter.nih.gov |
| EVALUATION AND TESTING SERVICES (ETS) FOR VACCINES AND OTHER BIOLOGICS FOR INFECTIOUS DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $10,000 | September 30, 2025 | September 29, 2035 | FUSCO, PETER | reporter.nih.gov |
| Preclinical Services for Biopharmaceutical Product Development | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $2,158 | September 8, 2023 | September 7, 2030 | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 3 | $257,586 | 0 | $0 |
| 2024 | 2 | $1,817,396 | 0 | $0 |
| 2023 | 5 | $3,650,059 | 0 | $0 |
| 2022 | 3 | $5,338,531 | 0 | $0 |
| 2021 | 1 | $2,823,837 | 0 | $0 |
Topics of its NIH awards
- Infectious Diseases
- Clinical Research
- Biotechnology
- Emerging Infectious Diseases
- Antimicrobial Resistance
- Translational Research
- Prevention
- Biodefense and Related Countermeasures
- Clinical Trials and Supportive Activities
- Orphan Drug
- Rare Diseases
- Health Services
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.